21 matches for your search in the start-up spotlight
rss
Cambridge-based TRIMTECH Therapeutic’s mission is to create novel small molecule degraders of protein aggregates that will combat neurodegenerative and inflammatory diseases including Alzheimer’s disease, a leading cause of death globally. The Company’s proprietary degrader technology is focused ...
DIOSynVax customises vaccine antigen design to maximise the protection that vaccines can provide worldwide against existing and future viruses. Grounded firmly in virus structure and evolution, our method is patent protected, combining computational biology with in vitro and in vivo validation, ...
NextPoint is advancing the field of immuno-oncology through its leading scientific work on the novel HHLA2 pathway. Our innovative approach integrates foundational science with a defined clinical biomarker to deliver a new class of monotherapies for patients who will not benefit from PD-1/L1 ...
Transine Therapeutics is developing a novel class of therapeutic RNAs that have the property to drive up protein expression with an unprecedented level of control and specificity: The SINEUP® platform. Our SINEUPs are designed to precisely bind to a target mRNA and boost expression of almost any ...
METiS Therapeutics is a discovery technology and therapeutics company that has the potential to drive best-in-class drug assets in a wide range of therapeutic areas. The METiS platform (AiTEM) combines state-of-the-art AI data-driven algorithms, mechanism-driven quantum mechanics and molecular ...
Cellino is on a mission to make personalized, autologous cell therapies accessible for patients. Stem cell-derived regenerative medicines are poised to cure some of the toughest diseases within this decade, including Parkinson’s, diabetes, and heart disease. Patient-specific cells provide the ...
EQRx is a new type of pharmaceutical company committed to developing and delivering innovative medicines to patients at radically lower prices. Launched in January 2020, EQRx is purpose-built, at scale, with a growing catalog of medicines in development in high-cost drug categories and emerging ...
PhoreMost is a new-model drug discovery company based in Cambridge, UK: Using its core expertise to open up new ‘druggable' target space and working with a global network of co-invested academic and industrial collaboration partners, we aim to bring a wide array of novel ‘targeted' therapies more ...
At Quench Bio we are discovering inhibitors of novel targets in innate immunity, the gasdermins. A central player in multiple pathways leading to inflammatory cell death, Gasdermin D acts as the executioner of pyroptosis and NETosis. By targeting this core node in innate immunity, we will inhibit ...
nQ Medical's artificial intelligence technology has shown in four years of clinical trials at MIT to substantially change the way disease is managed for a wide range of neuromotor and neurocognitive disorders. nQ focuses on analysis of user interaction with common electronic devices to capture ...
